73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Cassava Sciences Inc
Closed
SectorHealthcare
2.03 -4.69
Overview
Share price change
24h
Min
2.02
Max
2.04
Income | 33M -11M |
|---|---|
Sales | 840K 840K |
Profit margin | -1,286.548 |
Employees | 30 |
EBITDA | 35M -11M |
Next Earnings | 2 Mar 2026 |
|---|
Market Cap | -4.3M 142M |
|---|---|
Previous open | 6.72 |
Previous close | 2.03 |
News Sentiment
By Acuity
50%
50%
138 / 361 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
Cassava Sciences Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Cassava Sciences Inc Forecast
Sentiment
By Acuity
138 / 361 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Cassava Sciences Inc
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Live chat